TIAA CREF Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

TIAA CREF Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$227K	Buy	+8,673	New	+$190K	﹤0.01%	2863

Other funds holding YMAB

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TIAA CREF Investment Management's YMAB Position: Q1 2019 in Review

TIAA CREF Investment Management opened a new position in Y-mAbs Therapeutics (YMAB) in Q1 2019: 8,673 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #2863 among its holdings.

45 funds tracked by Wall St. Rank hold YMAB as of Q1 2019.

TIAA CREF Investment Management held 8,673 shares of Y-mAbs Therapeutics worth $227K as of Q1 2019.
Y-mAbs Therapeutics was a new TIAA CREF Investment Management position in Q1 2019.
Y-mAbs Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2863 holding.
45 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.